Actinium Pharmaceuticals

$10.80
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.13 (-1.19%) As of 3:47 PM UTC today

Why Robinhood?

You can buy or sell ATNM and other stocks, options, and ETFs commission-free!

About ATNM

Actinium Pharmaceuticals, Inc, also called Actinium Pharmaceuticals, is a clinical-stage biopharmaceutical company. It is focused on developing Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. The firm provides its service through Iomab-B, which is studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The company was founded in 2002 and is headquartered in New York, NY. The listed name for ATNM is Actinium Pharmaceuticals, Inc.

CEO
Sandesh Seth
Employees
25
Headquarters
New York, New York
Founded
2000
Market Cap
148.57M
Price-Earnings Ratio
Dividend Yield
Average Volume
485.08K
High Today
$11.15
Low Today
$10.71
Open Price
$11.02
Volume
191.78K
52 Week High
$19.47
52 Week Low
$4.71

Collections

ATNM Earnings

-$0.41
-$0.27
-$0.14
$0.00
Q4 FY18
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
per share
Actual
-$0.36 per share

You May Also Like